Background: Copy number alterations (CNAs) and losses of heterozygosity (LOHs) are common events in cervical cancer. The profiles of these genomic alterations are thought to differ from ethnicity to ethnicity. Thus, in this work, we sought to identify the recurrent genomic alterations that are present in cervical cancer patients of Malay and non-Malay ethnicities in the multiethnic Malaysian population. Methods: Genome-wide analysis of CNAs and LOHs was performed on DNA isolated from paired cancerous and non-cancerous cervical tissues of 54 Malay and 18 nonMalay patients by using AffymetrixCytoScan HD Array. Recurrent genomic alterations were then identified by manual counting. Results: The top three most common recurrent copy number gains (CN gains) were identical in both Malay and non-Malay patients, while slight differences were present for the recurrent copy number losses (CN losses) and LOHs profiles. Among both groups,the 3q21.3, 10q26.3 and 5p15.33 loci were the most frequently observed genomic regions containing the recurrent CN gains (having present in 53.7%, 53.7%, 50.0% of Malay patients and 50.0%, 44.4%, 38.9% of non-Malay patients respectively). For CN losses, the most commonly recurring genomic loci among the Malays were 11p11.12 (66.7%), Xp11.1 (51.9%), 12q11 (35.2%) and 5p12 (35.2%), while those among the non-Malays were 3p11.1 (61.1%), 11p11.12 (61.1%), Xp11.1 (55.6%), 12q11 (55.6%). Besides, for LOHs, Xq11.1, Xq22.3 and 16p11.2 loci, were the most commonly altered regions among the Malays (observed in 94.4%,55.6% and 46.3% of the specimens), while those among the non-Malay patients were Xq11.1 (94.4%), Xp11.23 (61.1%) and Xq22.3 (55.6%) loci. Conclusion: We successfully identified a number of genomic loci containing the commonly recurring genomic alterations in cervical cancer patients of Malay and nonMalay ethnicities, and demonstrated that minor differences existed in the genomic alteration profiles of Malay and non-Malay patients.
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There are no potential tumor markers validated for prognosis of endometrial cancer. In this study, we investigated diagnostic and prognostic applications of serum CA19-9 for endometrial cancer. Between January 2006 and December 2012, serum CA19-9 levels were examined in patients with endometrial cancer, and were then determined during treatment and at scheduled follow-up examinations in patients with elevated baseline serum CA19-9 levels. During this period, a total of 215 patients were treated for endometrial cancer. The median age was 60 years (28-85). Subsequently 52 patients (24.2%) relapsed at the time of the last folow-up and the median follow-up time was 62 months (1-113). Elevated serum CA19-9 levels were identified in 63 patients (29.3%) and were associated with clinical stage, myometrial invasion depth, lymph node metastasis, distant metastasis, and menopausal status. Elevated serum CA19-9 levels were not related to histological type, histological grade, age, body mass index, or relapse of disease. Among the 63 patients with elevated serum CA19-9 levels, 52 (82.5%) achieved remission and serum CA19-9 levels returned to the normal range in 50 cases (96.2%). Seven patients (13.5%) had relapses among these patients and serum CA19-9 level has been elevated again in all cases. Serum CA19-9 levels are a potential prognostic indicator for endometrial cancer. Purpose: To retrospectively evaluate clinical outcomes of radiofrequency ablation (RFA) and cryoablation for cT1b renal cell carcinoma (RCC) using multi-center data.
Materials and Methods: Data of 45 patients (38 males and 7 females, median age; 74, range; 39-87) with 45 RCCs of 4.1-6.5cm (median; 4.5cm) were acquired from 3 institutions. RFA and cryoablation was performed for 23 and 22 patients, respectively. Technical success, safety, local tumor progression, and survival were evaluated. Safety was evaluated by using Common Terminology Criteria for Adverse Events version 4.0. Results: The tumors were completely ablated by first ablation in 36 patients, so initial technical success rate was 80% (36/45). Initial success rate was significantly lower in RFA (p ¼ 0.02). Seven tumors were completely ablated by additional ablation, so secondary technical success rate was 96% (43/45). Grade-1, -2, and -3 complications occurred in 30, 8, and 3 cases, respectively. They recovered by conservative treatment. There were no significant differences in complication rate between RFA and cryoablation (p ¼ 0.23). Local tumor progression occurred in 6 and 1 patients after RFA and cryoablation, respectively (p ¼ 0.10). Female (p < 0.01), tumor size of 5cm or more (p ¼ 0.03), ventral side tumor (p ¼ 0.03), and single kidney (p ¼ 0.04) were detected as significant risk factors of local tumor progression. During the median follow up of 11.6 months, 3 patients died of heart disease (n ¼ 2) and lung cancer (n ¼ 1). The 5-year overall survival rates were 83.5% (95% confidence interval, 49.2-95.5%). No significant prognostic factor was detected. Conclusion: Both RFA and cryoablation are feasible and useful therapeutic options for the treatment of cT1b RCC.
O3 À 15 À 2 A NHO network surveillance for constructing the safe handling system of hazardous drugs in Japan (2nd report) Background: Much labor has been devoted to regulate occupational exposure to hazardous drugs (HD) and to improve the HD protective modalities in the USA and Europe according to the alert from National Institute for Occupational Safety and Health (NIOSH), the United States Pharmacopoeia (USP) 800, and other HD handling guidelines. In Japan, after the Joint guideline for preventing drug exposure on cancer treatment published in 2015, the interest for the safe handling of HD among medical professionals has been increasing. However, the guideline implementation in Japan is not enough yet compared to the USA and Europe. We have planned and started the multi-institutional surveillance of HD exposure in the National Hospital Organization (NHO) hospitals since Feb 2016. Methods&Results: The HD exposure surveillance is now being performed in 32 NHO hospitals mainly by using the sampling sheet method 3 times in 2-year study period. Other surveillances regarding HD handling systems in each hospital and commitment emotions of the staff to their own institutes have been also performed. The surveillance results of HD exposure, HD handling systems for preventing exposures, and staff commitment emotions will be presented in the presentation. Conclusion: The HD exposure surveillance is an important trial for constructing the safe handling system in Japan.
O3 À 15 À 3 Review of cases with exposure to anti-cancer drugs and the alteration of fixation method using I-cut gauze in CV port 
Chemotherapy Team
Background: It is mandatory to be cautious about the exposure to the chemotherapeutic agents for the safety of medical staffs as well as patients. Methods: The cases with exposure to hazardous agents were examined during 2012 and 2016 using the incident reports and medical records and its countermeasures were discussed by multidisciplinary team. As a result, I-cut gauze was introduced instead of Ycut one for the fixation of needle on the central venous (CV) port in 2015, aiming at reducing the risk of extravasation and needle disengagement. The usefulness of this alteration was evaluated by comparing the rates of exposure incident between before and after one year of revision. Statistical analyses were performed with Fishers exact test by EZR. Results: During these 5 years 48 cases were identified as the exposure to anticancer drugs, 23 with CV port, 18 with peripheral vein infusions, and 7 with other reasons. The numbers of exposure incident to each drug were 5-FU, 12 cases among 3559 (0.3%), cisplatin, 6 cases among 418 (1.4%), ifosfamide, 4 cases among 631 (0.6%), and cytarabine, 1 case among 1237 (0.08%). The rate of CV port-associated exposure was decreased with the change of fixation method (Y-cut 5 cases among 1041 versus I-cut 4 cases among 1025, p < 0.0001) Conclusions: The alteration of fixation method using I-cut gauze has been proved to reduce the risk of exposure to antineoplastic agents in CV port. Careful review of the incident and taking countermeasures by multidisciplinary team are useful to improve the safety management of cancer chemotherapy.
